Search

Your search keyword '"Miles, Douglas"' showing total 361 results

Search Constraints

Start Over You searched for: Author "Miles, Douglas" Remove constraint Author: "Miles, Douglas"
361 results on '"Miles, Douglas"'

Search Results

1. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

3. Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

4. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

5. aProceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

7. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

8. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

9. Novel insights into metabolic-associated steatotic liver disease preclinical models

12. P18 Glutaminolysis and Steatosis to Steatohepatitis Transition: Role of Glutaminase

15. Endothelial and platelet-derived microvesicles as a biomarker of cardiovascular risk in patients with metabolic dysfunction-associated fatty liver disease (MAFLD)

16. Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study

17. Transcription and FACT facilitate the restoration of replication-coupled chromatin assembly defects

18. A second update on mapping the human genetic architecture of COVID-19

19. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

20. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity

21. Supplementary material to: Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

22. Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

24. Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD.

25. Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients

26. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

27. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

28. Cysteinyl leukotrienes pathway genes, atopic asthma and drug response: From population isolates to large genome-wide association studies.

30. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

31. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD

32. Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients

33. Novel genes and sex differences in COVID-19 severity

34. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

35. Supplementary files of the article 'Novel genes and sex differences in COVID-19 severity' [Dataset]

36. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

37. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD

38. Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma

39. Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients

40. Novel genes and sex differences in COVID-19 severity

41. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

42. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

43. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

44. L

45. Flexible Data Distribution in PGHPF

46. Long non‐coding RNA H19 as a biomarker for hepatocellular carcinoma

47. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

48. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD

49. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

50. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

Catalog

Books, media, physical & digital resources